PF-Atlas › Clinical Trials › NCT04116502
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
Ruxolitinib · Phase 3
Registry ID
NCT04116502
Phase
Phase 3
Status
Recruiting
Drug / intervention
Ruxolitinib
Sponsor
University of Birmingham
Start
2019-10-25
About this trial
Ruxolitinib is evaluated in NCT04116502, a Phase 3 idiopathic pulmonary fibrosis study sponsored by University of Birmingham. Current status: Recruiting.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT04116502 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.